back

Crizanlizumab

Subject:

  • Active Substance: Crizanlizumab
  • Name: Adakveo
  • Therapeutic area: Haematology - Hemostaseology
  • Pharmaceutical company: Novartis Pharma GmbH

 

Time table:

  • Publication of project plan: 28.07.2020
  • Publication of final assessment: 25.11.2020

 

Assessment information:

  • Title: Crizanlizumab for the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and over
  • Author/Co-Author: ZIN (Netherlands), AEMPS (Spain)
  • Dedicated Reviewers: HAS (France), NICE (UK), JAZMP (Slovenia)